ClinicalTrials.gov
public full text
Public Domain
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trial of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer#846020
- Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT#1140890
- Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation#860124
- Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications#452362
- An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry#994148
Record · ID 867819
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive